经肝动脉化疗栓塞联合射频消融治疗原发性肝细胞癌合并门静脉癌栓的预后影响因素分析

doi:10.19401/j.cnki.1007-3639.2018.03.009

中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (3): 222-228.doi: 10.19401/j.cnki.1007-3639.2018.03.009

经肝动脉化疗栓塞联合射频消融治疗原发性肝细胞癌合并门静脉癌栓的预后影响因素分析

肖金成¹，康鑫鑫²，白淇文¹，李　靖¹

1. 郑州大学附属肿瘤医院微创介入科，河南郑州 450003 ；
2. 郑州大学第一附属医院麻醉科，河南郑州 450052

出版日期:2018-03-30 发布日期:2018-04-11
通信作者: 李　靖　Email: jingli_zz@163.com
基金资助:
2017年河南省医学科技攻关项目（201702261）。

Investigation of prognostic factors of primary hepatocellular carcinoma with portal vein tumor thrombus after transcatheter arterial chemoembolization combined with radiofrequency ablation

XIAO Jincheng¹, KANG Xinxin², BAI Qiwen¹, LI Jing¹

1. Department of Intervention, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China; 2. Department of Anesthesiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

Published:2018-03-30 Online:2018-04-11
Contact: LI Jing E-mail: jingli_zz@163.com

摘要/Abstract

摘要：

背景与目的：经肝动脉化疗栓塞（transcatheter arterial chemoembolization，TACE)是否为治疗原发性肝细胞癌（hepatocellular carcinoma，HCC）合并门静脉癌栓（portal vein tumor thrombus，PVTT）的绝对禁忌，目前尚无定论。该研究旨在探讨TACE联合射频消融（radiofrequency ablation，RFA）治疗HCC合并PVTT的预后影响因素。方法：回顾性分析2011年1月1日—2013年12月31日于郑州大学附属肿瘤医院行TACE联合RFA治疗的HCC合并PVTT的157例患者的临床资料及随访数据，单因素及多因素Cox回归分析人口学资料、实验室指标及临床资料与生存时间和肿瘤转移复发情况的关系。结果：多因素Cox回归结果显示，在调整和控制其他因素后，血清白蛋白（albumin，ALB）水平为TACE联合RFA治疗后HCC合并PVTT患者3年生存及降低肿瘤复发转移风险的保护性因素，术前甲胎蛋白（alpha-fetoprotein，AFP）、丙氨酸转氨酶（alanine aminotransferase，ALT）、天门冬氨酸转氨酶（aspartate transaminase，AST）水平、门静脉癌栓部位及肝功能Child Pugh分级为患者3年生存的独立危险因素；AFP、AST水平及门静脉癌栓部位为肿瘤复发转移的独立危险因素。结论：TACE联合RFA并非治疗HCC合并PVTT的绝对禁忌，在治疗前对患者进行相关因素评估有助于更好地选择治疗方法和时机，从而提高HCC治疗水平。

关键词: 经肝动脉化疗栓塞, 射频消融, 原发性肝细胞癌, 门静脉癌栓, 预后

Abstract:

Background and purpose: There is still no definite conclusion whether transcatheter arterial chemoembolization (TACE) is an absolute contraindication to the treatment for primary hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Aim of the current study was to investigate the prognostic factors of HCC with PVTT treated by TACE combined with radiofrequency ablation (RFA). Methods: We retrospectively analyzed the medical records and follow-up data of 157 patients who underwent TACE combined with RFA in the Affiliated Tumor Hospital of Zhengzhou University from January 1, 2011 to December 31, 2013. The relationships between demographic data, serological markers, clinical data and 3-year survival rate, tumor metastasis and recurrence were analyzed by univariate and multivariate Cox regression analysis. Results: Multivariate Cox regression analysis showed that higher serum albumin (ALB) level was the protective factor for the survival of patients with HCC and PTVV after TACE combined with RFA treatment and reduced the risk of tumor recurrence and metastasis after adjustment and control of other factors. High levels of alpha-fetoprotein (AFP), alanine aminotransferase (ALT) and aspartate transaminase (AST), portal vein trunk suppositories and mixed tumor thrombus, and higher stage of the Child Pugh classification were independent risk factors of 3-year survival. High levels of AFP and AST, portal vein trunk suppositories and mixed tumor thrombus were independent risk factors of tumor recurrence and metastasis. Conclusion: TACE combined with RFA is not an absolute contraindication for the treatment of HCC with PVTT, the prognosis affected by a variety of factors. Evaluating the relevant factors of each patient before treatment may be helpful in choosing the better indications and assessing the possible prognosis to improve HCC treatment.

Key words: Transcatheter arterial chemoembolization, Radiofrequency ablation, Primary hepatocellular carcinoma, Portal vein tumor thrombus, Prognosis

肖金成,康鑫鑫,白淇文,等. 经肝动脉化疗栓塞联合射频消融治疗原发性肝细胞癌合并门静脉癌栓的预后影响因素分析[J]. 中国癌症杂志, 2018, 28(3): 222-228.

XIAO Jincheng, KANG Xinxin, BAI Qiwen, et al. Investigation of prognostic factors of primary hepatocellular carcinoma with portal vein tumor thrombus after transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. China Oncology, 2018, 28(3): 222-228.

[1]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[2]	马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[3]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[4]	高鹤丽, 徐　近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.
[5]	巩润泽, 胡海燕. CCL2在骨肉瘤组织中的表达及其临床意义[J]. 中国癌症杂志, 2021, 31(6): 455-459.
[6]	彭子珊, 孔　辉, 鲍　真, 赵红杏, 刘　鑫, 卢韶华. 83例多发肺腺癌患者的临床病理学特征分析[J]. 中国癌症杂志, 2021, 31(5): 408-418.
[7]	肖　锋, 肖静文, 邵建国, 陈丽燕, 顾春燕 . PD-1在肝细胞癌肿瘤浸润淋巴细胞中的表达及与预后的相关性[J]. 中国癌症杂志, 2021, 31(5): 419-427.
[8]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[9]	武元元 , 王　军 , 刘勤江 , 张　明 . 甲状腺未分化癌的预后因素分析及治疗决策[J]. 中国癌症杂志, 2021, 31(3): 212-220.
[10]	杨柳松, 祝迎锋, 唐剑敏 . 上皮样胶质母细胞瘤10例报告并文献复习[J]. 中国癌症杂志, 2021, 31(2): 114-120.
[11]	丁平安, 张志栋, 杨沛刚, 林叶成, 田　园, 徐校胜, 吴　娟, 刘　颖, 郭洪海, 刘　洋, 王　冬, 檀碧波, 李　勇, 赵　群 . 胃癌脑膜转移的临床病理学特征及预后分析[J]. 中国癌症杂志, 2021, 31(2): 126-135.
[12]	周宏宇, 李浩然, 程　玺, 陈丽华, 杨雨菲, 常　彬 . 11例卵巢高钙血症型小细胞癌临床分析并文献复习[J]. 中国癌症杂志, 2021, 31(2): 136-142.
[13]	李　飞, 宋　媛, 李　芳, 朱希燕, 何　明 . 食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究[J]. 中国癌症杂志, 2021, 31(2): 143-150.
[14]	李盼盼, 张　卓. 42例原发性中枢神经系统淋巴瘤患者预后影响因素分析[J]. 中国癌症杂志, 2021, 31(12): 1194-1201.
[15]	卢大松, 冯勇军, 王武峰, 牟忠林, 赵　娜. 个体化营养干预对局部晚期鼻咽癌患者生活质量及生存预后的影响[J]. 中国癌症杂志, 2021, 31(12): 1202-1208.

经肝动脉化疗栓塞联合射频消融治疗原发性肝细胞癌合并门静脉癌栓的预后影响因素分析

Investigation of prognostic factors of primary hepatocellular carcinoma with portal vein tumor thrombus after transcatheter arterial chemoembolization combined with radiofrequency ablation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价